Needham Maintains Buy on Vaxcyte, Raises Price Target to $140
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer maintains a Buy rating on Vaxcyte (NASDAQ:PCVX) and raises the price target from $95 to $140.
September 03, 2024 | 5:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reaffirmed a Buy rating for Vaxcyte and increased the price target significantly from $95 to $140, indicating strong confidence in the company's future performance.
The increase in the price target from $95 to $140 by a reputable analyst suggests a positive outlook for Vaxcyte's stock. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100